Agnieszka Lisowska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Agnieszka Lisowska has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Małgorzata Kozłowska-Wojciechowska
Department of Clinical Pharmacy and Pharmaceutical Care, Medical University of Warsaw, 02-091 Warsaw, Poland
4 shared publications - Magdalena Makarewicz-Wujec
Faculty of Medical and Health Sciences, VIZJA University, 01-043 Warsaw, Poland
3 shared publications - Anna Maria Dworakowska
Department of Pharmacotherapy and Pharmaceutical Care, Faculty of Pharmacy, Medical University of Warsaw, 02-097 Warsaw, Poland
2 shared publications Agnieszka Serafin
Med Univ Warsaw, Chair & Dept Cardiol 1, Ul Banacha 1a, PL-02097 Warsaw, Poland
1 shared publicationAnna Dworakowska
1 shared publication- Edyta Czepielewska
Institute of Pharmaceutical Care, VIZJA University, Okopowa Street 59, 01-043 Warsaw, Poland
1 shared publication
Latest Publications
- Open Access
- 1 January 2021
- Published by Polish Pharmaceutical Society in Acta Poloniae Pharmaceutica - Drug Research
- Vol. 78 (6) , 863-867
Intentional non-adherence to medications in the elderly – results from a pilot study (Warsaw, Poland)
- 1 January 2021
- Published by Polish Pharmaceutical Society in Acta Poloniae Pharmaceutica - Drug Research
- Vol. 78 (6) , 863-867
Open AccessIntentional non-adherence to medications in the elderly – results from a pilot study (Warsaw, Poland)
- Open Access
- 1 January 2020
- Published by Polish Pharmaceutical Society in Acta Poloniae Pharmaceutica - Drug Research
- Vol. 77 (6) , 963-969
‘IF I KNEW THAT IT COULD HELP...' – FACTORS INFLUENCING ADHERENCE TO TREATMENT AFTER MYOCARDIAL INFARCTION – RESULTS FROM A QUALITATIVE STUDY GUIDED BY HEALTH BELIEF MODEL
- 1 January 2020
- Published by Polish Pharmaceutical Society in Acta Poloniae Pharmaceutica - Drug Research
- Vol. 77 (6) , 963-969
Open Access‘IF I KNEW THAT IT COULD HELP...' – FACTORS INFLUENCING ADHERENCE TO TREATMENT AFTER MYOCARDIAL INFARCTION – RESULTS FROM A QUALITATIVE STUDY GUIDED BY HEALTH BELIEF MODEL
- 5 February 2019
- Published by Hindawi Limited in Journal of Clinical Pharmacy and Therapeutics
- Vol. 44 (3) , 471-478
Adherence to guidelines for pharmacological treatment of young adults with myocardial infarction in Poland: Data from Polish Registry of Acute Coronary Syndromes (PL‐ACS)
What is known and objective Myocardial infarction (MI) in young adults accounts for up to 10% of all cases. Regarding life expectancy and professional activity, it is extremely important to restore and maintain young patients’ full performance. Therefore, secondary prevention is especially vital in this group of patients. The paper focuses on the analysis of pharmacotherapy in young MI patients in Poland, assessing disparities between the European Society of Cardiology guidelines and clinical practice, and regional differences among the provinces. Methods The analysis was conducted using the data from a nationwide, observational, multicentre, prospective study—the Polish Registry of Acute Coronary Syndromes (PL‐ACS). The data were collected from patients ≤45 years old with MI who were hospitalized in the period 2010‐2014. Results and discussion A retrospective study included 6367 MI patients. They constituted 3.9% of all the patients with MI in Poland. Despite the fact that during hospitalization regional differences were observed in case of acetylsalicylic acid (range 70.3%‐93.8%), β‐blockers (range 50.0%‐79.6%), statins (range 53.4%‐85.7%) and angiotensin‐converting enzyme inhibitors (range 46.9%‐75.0%), the majority of patients received the drugs according to the guidelines. Regional differences found at discharge also regarded those medications, but the range of observed variations was smaller. On average, three‐quarter of patients received guideline‐recommended medications. Still, in some provinces, almost a quarter of patients were administered those medications only at discharge. What is new and conclusion In the study population, there were significant differences between the provinces regarding pharmacotherapy during hospitalization, which concerned major groups of medications. However, pharmacotherapy indicated at discharge revealed fewer regional differences and adhered to guideline recommendations to a greater extent. Nevertheless, there is still some room for improvement, especially with regard to pharmacotherapy during hospitalization.
- 5 February 2019
- Published by Hindawi Limited in Journal of Clinical Pharmacy and Therapeutics
- Vol. 44 (3) , 471-478
Adherence to guidelines for pharmacological treatment of young adults with myocardial infarction in Poland: Data from Polish Registry of Acute Coronary Syndromes (PL‐ACS)
What is known and objective Myocardial infarction (MI) in young adults accounts for up to 10% of all cases. Regarding life expectancy and professional activity, it is extremely important to restore and maintain young patients’ full performance. Therefore, secondary prevention is especially vital in this group of patients. The paper focuses on the analysis of pharmacotherapy in young MI patients in Poland, assessing disparities between the European Society of Cardiology guidelines and clinical practice, and regional differences among the provinces. Methods The analysis was conducted using the data from a nationwide, observational, multicentre, prospective study—the Polish Registry of Acute Coronary Syndromes (PL‐ACS). The data were collected from patients ≤45 years old with MI who were hospitalized in the period 2010‐2014. Results and discussion A retrospective study included 6367 MI patients. They constituted 3.9% of all the patients with MI in Poland. Despite the fact that during hospitalization regional differences were observed in case of acetylsalicylic acid (range 70.3%‐93.8%), β‐blockers (range 50.0%‐79.6%), statins (range 53.4%‐85.7%) and angiotensin‐converting enzyme inhibitors (range 46.9%‐75.0%), the majority of patients received the drugs according to the guidelines. Regional differences found at discharge also regarded those medications, but the range of observed variations was smaller. On average, three‐quarter of patients received guideline‐recommended medications. Still, in some provinces, almost a quarter of patients were administered those medications only at discharge. What is new and conclusion In the study population, there were significant differences between the provinces regarding pharmacotherapy during hospitalization, which concerned major groups of medications. However, pharmacotherapy indicated at discharge revealed fewer regional differences and adhered to guideline recommendations to a greater extent. Nevertheless, there is still some room for improvement, especially with regard to pharmacotherapy during hospitalization.
- 13 July 2017
- Published by Taylor & Francis in Substance Use & Misuse
- Vol. 52 (13) , 1712-1720
Can “Legal Highs” Trigger Myocardial Infarction? Patients' Characteristics Based on Published Cases
(2017). Can “Legal Highs” Trigger Myocardial Infarction? Patients' Characteristics Based on Published Cases. Substance Use & Misuse: Vol. 52, No. 13, pp. 1712-1720.
- 13 July 2017
- Published by Taylor & Francis in Substance Use & Misuse
- Vol. 52 (13) , 1712-1720
Can “Legal Highs” Trigger Myocardial Infarction? Patients' Characteristics Based on Published Cases
(2017). Can “Legal Highs” Trigger Myocardial Infarction? Patients' Characteristics Based on Published Cases. Substance Use & Misuse: Vol. 52, No. 13, pp. 1712-1720.
- 13 October 2016
- Published by Polskie Towarzystwo Kardiologiczne in Polish Heart Journal
- Vol. 74 (10) , 1148-1153
Risk factors, prognosis, and secondary prevention of myocardial infarction in young adults in Poland
- 13 October 2016
- Published by Polskie Towarzystwo Kardiologiczne in Polish Heart Journal
- Vol. 74 (10) , 1148-1153
Risk factors, prognosis, and secondary prevention of myocardial infarction in young adults in Poland